Chesapeake Corp

Chesapeake — Shareholder Meeting (April 2007)

24 slides from Chesapeake's shareholder meeting presentation, Apr 30, 2007

  1. Slide 1: Chesapeake Annual Meeting

    April 25, 2007 Chesapeake Annual Meeting

  2. Slide 2: Financial Highlights

    Financial Highlights • Net sales decr eas ed 1% to $995.4 million Operating income* of $44.9 million compared to $47.7 million in 2005 • • Reported net loss per share of $1.67 Excludes gains or losses on divestitures, impairment and restructuring charges, and loss on extinguishment of debt. *

  3. Slide 3: Earnings Per Share: Reconciliation of Reported to Adjusted EPS

    Earnings Per Share Reconciliation of Reported to Adjusted EPS

  4. Slide 4: Operating Income vs. 2006

    * Excludes gains or losses on divestitures and impairment, restructuring costs and loss on extinguishment of debt. Operating Income* ($ in millions) vs. 2006

  5. Slide 5: Proactive Management of Pension Obligations

    • U.S. defined benefit plan benefits frozen; U.S. qualified plan fully funded • U.K. plan closed to new entrants • Incremental total funding in 2004-2006 of $35 million • Total plan deficits reduced from $153 million at YE 2005 to $96 million at YE • Future improvements expected Proactive Management

  6. Slide 6: $25-Million Cost Savings Program

    $25-Million Cost Savings Program • $16 million in annualized savings to date • Closed three plants: – Birmingham, England – Bedford, England – Ezy sur Eure, France • Sold French luxury packaging business • Sold plastics operation in Northern Ireland

  7. Slide 7: Operational Excellence & Cost Savings News

    Operational Excellence & @ichesapeake" Cost Saving News f = be Ss Chesapeake

  8. Slide 8: Growth Initiatives

    Growth Initiatives “As important as continuous cost savings are to our organization, I want to assure you that we understand that a vibrant organization needs growth as well to be successful.” 4 th Quarter Earnings Conference Call

  9. Slide 9: Blue Chip Pharma Customers

    Blue Chip Pharma Customers

  10. Slide 10: Braille Pharma Packs

    Braille Pharma Packs

  11. Slide 11: Anti-Counterfeiting Solutions

    Anti-Counterfeiting Solutions

  12. Slide 12: New China Paperboard Plant

    New China Paperboard Plant • Enables growth opportunities in Pharma • World-Class facility • Offers anti-counterfeiting solutions

  13. Slide 13: SPARK High

    IGuian SPARK High Chesapeake’

  14. Slide 14: East Kilbride Modernization

    East Kilbride Modernization

  15. Slide 15: Lithoprint Relocation

    Lithoprint Relocation • State-of-the-art facility for alcoholic drinks labels • Enthusiastic customer response

  16. Slide 16: Agrochemical Twinpack

    Agrochemical Twinpack

  17. Slide 17: Hungarian Joint Venture

    Hungarian Joint Venture • Will produce large specialty plastic containers for agrochemicals and specialty chemicals markets • Supporting major contract with Syngenta • Near Budapest with established JV partner

  18. Slide 18: African Operations

    Cape Town Harrismith Mauritius African Operations

  19. Slide 19: #1 Focus -- Increase Cash Flow and Profitability

    Cost Savings Program - $25 million Organic Growth - Worldwide pharmaceutical packaging demand expected to grow 5% per year to 2009, CSK position with majority of top 20 global pharmaceutical companies Strategic Initiatives - Arlington Press, South Africa, China, Hungarian JV Increased Cash Flow & Pr

  20. Slide 20: Operating Earnings

    Operating Earnings “We are convinced we are making the right moves; however, an improvement in operating earnings, exclusive of costs associated with our global cost savings program, will be a challenge in 2007.” 4 th Quarter Earnings Conference Call

  21. Slide 21: Thank you for your continued support

    Thank you for your continued support.

  22. Slide 22: Non-GAAP Financial Measures

    xzzzzz Non-GAAP Financial Measures Operating income from continuing operations, in each case exclusive of losses associated with the extinguishments of debt, restructuring expenses, asset impairments, gains or losses on divestitures, and goodwill impairment are non-GAAP financial measures. The compa

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    Disclaimer Full Year RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ($ in millions) Operating (loss) income $ 0.3 $ (277.8 ) Add: goodwill impairment charge $ 14.3 $ 312.0 Add: restructuring expenses, asset impairments and other exit costs $ 33.4 $ 10.7 Less/Add: (gain) loss on divestitures $ (3.1 )

  24. Slide 24: Chesapeake Annual Meeting

    April 25, 2007 Chesapeake Annual Meeting

Chesapeake — Shareholder Meeting (April 2007) on 6ix